GRTX - Galera Therapeutics Inc

0.1452
0.145   100.000%

Share volume: 0
Last Updated: 06-03-2024

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
N/A
N/A
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-0.40%
1 Year
-54.07%
2 Year
-97.21%
Key data
Stock price
$0.15
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$1.11
52 WEEK RANGE
$0.05 - $0.24
52 WEEK CHANGE
-$54.46
MARKET CAP 
7.887 M
YIELD 
N/A
SHARES OUTSTANDING 
54.392 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: J. Mel Sorensen
Region: US
Website: galeratx.com
Employees: 30
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Galera Therapeutics, Inc. focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the. treatment of. radiotherapy induced severe oral mucositis in patients with head and neck cancer.

Recent news
loading